Tweedy Browne Co LLC Sells 26,410 Shares of Kenvue Inc. (NYSE:KVUE)

Tweedy Browne Co LLC lowered its stake in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 6.9% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 356,796 shares of the company's stock after selling 26,410 shares during the period. Kenvue makes up 0.5% of Tweedy Browne Co LLC's investment portfolio, making the stock its 24th biggest holding. Tweedy Browne Co LLC's holdings in Kenvue were worth $7,618,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in the stock. Grove Bank & Trust boosted its stake in Kenvue by 438.4% during the fourth quarter. Grove Bank & Trust now owns 1,163 shares of the company's stock worth $25,000 after buying an additional 947 shares in the last quarter. Geneos Wealth Management Inc. bought a new position in shares of Kenvue during the 4th quarter worth about $29,000. SRS Capital Advisors Inc. boosted its position in shares of Kenvue by 67.4% during the 4th quarter. SRS Capital Advisors Inc. now owns 1,418 shares of the company's stock valued at $30,000 after acquiring an additional 571 shares in the last quarter. Fortitude Family Office LLC increased its stake in Kenvue by 106.6% in the fourth quarter. Fortitude Family Office LLC now owns 1,506 shares of the company's stock valued at $32,000 after acquiring an additional 777 shares during the period. Finally, Versant Capital Management Inc raised its position in Kenvue by 300.8% in the fourth quarter. Versant Capital Management Inc now owns 1,920 shares of the company's stock worth $41,000 after purchasing an additional 1,441 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Remove Ads

Kenvue Trading Down 0.9 %

Shares of NYSE KVUE traded down $0.23 during mid-day trading on Thursday, hitting $23.65. The company's stock had a trading volume of 21,703,204 shares, compared to its average volume of 16,761,118. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46. The company's fifty day simple moving average is $22.50 and its 200-day simple moving average is $22.47. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The stock has a market cap of $45.19 billion, a price-to-earnings ratio of 44.61, a price-to-earnings-growth ratio of 2.62 and a beta of 1.25.

Kenvue (NYSE:KVUE - Get Free Report) last released its earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, hitting analysts' consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, sell-side analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were paid a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.47%. The ex-dividend date was Wednesday, February 12th. Kenvue's payout ratio is 154.72%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Piper Sandler lifted their price objective on Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a report on Monday, February 24th. Deutsche Bank Aktiengesellschaft cut Kenvue from a "buy" rating to a "hold" rating and lowered their price target for the company from $25.00 to $24.00 in a research report on Thursday, December 12th. UBS Group cut their price objective on Kenvue from $23.00 to $21.00 and set a "neutral" rating for the company in a report on Friday, February 7th. Citigroup reduced their target price on shares of Kenvue from $25.00 to $21.00 and set a "neutral" rating on the stock in a research note on Wednesday, January 15th. Finally, Royal Bank of Canada reiterated a "sector perform" rating and set a $24.00 target price on shares of Kenvue in a research report on Monday, February 3rd. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $24.00.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.